ReviewCurrent opinion in critical care2008
Novel strategies to combat bacterial virulence.
Review in Current opinion in critical care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Divergent mechanistic pathways of diarrheagenic bacterial infections at the host-microbiota interface: a review.Archives of microbiology · 2026Review
- Structural Insights into theInternational journal of molecular sciences · 2023Article
- Targeting multidrug resistantChemical science · 2023Article
- Eugenol-Functionalized Magnetite Nanoparticles Modulate Virulence and Persistence inMolecules (Basel, Switzerland) · 2021Article
- FKBP Ligands-Where We Are and Where to Go?Frontiers in pharmacology · 2018Review
- Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease.Applied microbiology and biotechnology · 2015Article
- Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets.Microbiology and molecular biology reviews : MMBR · 2014Review
- Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains.Intensive care medicine · 2012Article
- Quorum sensing in the context of food microbiology.Applied and environmental microbiology · 2012Review
- PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds.The Journal of biological chemistry · 2011Article
- The Staphylococcus aureus RNome and its commitment to virulence.PLoS pathogens · 2011Review
- Identification of a key amino acid of LuxS involved in AI-2 production in Campylobacter jejuni.PloS one · 2011Article
- Engineered single-domain antibodies with high protease resistance and thermal stability.PloS one · 2011Article
- Design of O-acetylserine sulfhydrylase inhibitors by mimicking nature.Journal of medicinal chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewIncidences of antimicrobial-resistant infections have increased dramatically over the past several decades and are associated with adverse patient outcomes. Alternative approaches to combat infection are critical and have led to the development of more specific drugs targeted at particular bacterial virulence systems or essential regulatory pathways. The purpose of this review is to highlight the recent developments in antibacterial therapy and the novel approaches toward increasing our therapeutic armory against bacterial infection. RECENT
findingsAlthough classic antibiotic development is not occurring rapidly, alternative therapeutics that target specific bacterial virulence systems are progressing from the discovery stage through the Food and Drug Administration approval process. Here we review novel antibodies that target specific virulence systems as well as a variety of newly discovered small molecules that block bacterial attachment, communication systems (quorum sensing) or important regulatory processes associated with virulence gene expression. SUMMARY: The success of novel therapeutics could significantly change clinical practice. Furthermore, the complications of collateral damage due to antibiotic administration, for example, suprainfections or decreased host immunity due to loss of synergistic bacterial communities, may be minimized using therapeutics that specifically target pathogenic behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.